spacer
home > white papers > R&D to Product: How to Reduce Costly Scale-Up Problems - Natoli Engineering Company, Inc.
WHITE PAPERS
logo_Natoli_Engo.jpg

Natoli Engineering Company, Inc.

phone +1 636 926 8900
email info@natoli.com
web http://www.natoli.com
email 28 Research Park Circle, Saint Charles, MO 63304, US

R&D to Product: How to Reduce Costly Scale-Up Problems

When scaling a new drug formulation from the development side of R&D into manufacturing, there is often a reality check with respect to process scaleup and performance of the formulation at production levels. Problems with capping/lamination and sticking/ picking are often first realized when a formulation is introduced to a level of compression required to supply market demand.
R&D to Product: How to Reduce Costly Scale-Up Problems
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

The global pharmaceutical solutions company on a mission to help manufacturers keep their supply chains moving

The current crisis in Europe has led to increasing energy insecurity and shortages of raw materials, which are creating severe pharmaceutical manufacturing supply line disruptions. In some cases, supplier lead times have doubled, prices are no longer certain, and orders are subject to cancellations or delays.
More info >>


White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement